Bristol-Myers Squibb’s combination treatment for multiple myeloma failed to hit the endpoint of progression-free survival in a Phase III test.
Shares of Karyopharm Therapeutics soared after the company posted positive Phase III results in multiple myeloma and announced plans for a regulatory submission in the second quarter of 2020 for a combination of Xpovio, Velcade and Dexamethasone.
Exploratory Analysis Shows Significant OS Results from Keytruda in KRAS Mutations
Blockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, European Society for Medical Oncology (ESMO), Exploratory Analysis, Keytruda, KRAS Mutations, Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Monotherapy, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), R&DFindings from the Phase III KEYNOTE-042 study show improvements in overall survival (OS), PFS and ORR in patients treated with Merck’s Keytruda (pembrolizumab) as a monotherapy.
Bristol-Myers Squibb’s Phase III CheckMate -548 study of Opdivo (nivoumab) added to current standard of care to treat brain cancer – newly diagnosed glioblastoma multiforme – did not meet one of the primary endpoints, progression-free survival. The clinical trial will continue to evaluate the other primary endpoint, overall survival.